{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T14:38:03Z","timestamp":1784299083833,"version":"3.55.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100011851","name":"Kom op tegen Kanker","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011851","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.ygyno.2020.09.025","type":"journal-article","created":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T21:34:25Z","timestamp":1601328865000},"page":"811-819","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors"],"prefix":"10.1016","volume":"159","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9808-7957","authenticated-orcid":false,"given":"C.","family":"Landolfo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.T.L.","family":"Achten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ceusters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7207-1519","authenticated-orcid":false,"given":"T.","family":"Baert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1398-9124","authenticated-orcid":false,"given":"W.","family":"Froyman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4945-8867","authenticated-orcid":false,"given":"R.","family":"Heremans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3984-2948","authenticated-orcid":false,"given":"A.","family":"Vanderstichele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Thirion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Van Hoylandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Claes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Oosterlynck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0138-4486","authenticated-orcid":false,"given":"A.S.","family":"Van Rompuy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3256-5850","authenticated-orcid":false,"given":"D.","family":"Schols","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4852-4340","authenticated-orcid":false,"given":"J.","family":"Billen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1613-7450","authenticated-orcid":false,"given":"B.","family":"Van Calster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1421-6059","authenticated-orcid":false,"given":"T.","family":"Bourne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2564-721X","authenticated-orcid":false,"given":"T.","family":"Van Gorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7589-8981","authenticated-orcid":false,"given":"I.","family":"Vergote","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3707-6645","authenticated-orcid":false,"given":"D.","family":"Timmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7321-4339","authenticated-orcid":false,"given":"A.","family":"Coosemans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2020.09.025_bb0005","first-page":"286","article-title":"Centralisation of services for gynaecological cancer","volume":"126","author":"Woo","year":"2012","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0010","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S1470-2045(18)30837-4","article-title":"Risk of complications in patients with conservatively managed ovarian tumours (IOTA5): a 2-year interim analysis of a multicentre, prospective, cohort study","volume":"20","author":"Froyman","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0015","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/gyno.2000.5811","article-title":"Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors","volume":"78","author":"Engelen","year":"2000","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0020","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1093\/jnci\/djm199","article-title":"Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125","volume":"99","author":"Van Calster","year":"2007","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0025","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1158\/0008-5472.CAN-04-3924","article-title":"Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas","volume":"65","author":"Drapkin","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0030","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ajog.2011.12.029","article-title":"Serum HE4 levels are less frequently elevated than CA125 in women with benign gynecologic disorders","volume":"206","author":"Moore","year":"2012","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0035","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0040","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/AOG.0b013e31821b5118","article-title":"Effectiveness of a multivariate index assay in the preoperative assessment of ovarian tumors","volume":"117","author":"Ueland","year":"2011","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0045","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ajog.2016.03.003","article-title":"Validation of a second-generation multivariate index assay for malignancy risk of adnexal masses","volume":"215","author":"Coleman","year":"2016","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0050","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2011.02.022","article-title":"No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting","volume":"121","author":"Jacob","year":"2011","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0055","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1038\/sj.bjc.6606092","article-title":"HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the risk of ovarian malignancy algorithm","volume":"104","author":"Van Gorp","year":"2011","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2020.09.025_bb0060","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1097\/AOG.0b013e31823584db","article-title":"Performance of the American college of obstetricians and gynecologists ovarian tumor referral guidelines with a multivariate index assay","volume":"118","author":"Timmerman","year":"2011","journal-title":"Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0065","doi-asserted-by":"crossref","first-page":"4664","DOI":"10.1158\/1078-0432.CCR-16-0316","article-title":"A prospective evaluation of early detection biomarkers for ovarian cancer in the European EPIC cohort","volume":"22","author":"Terry","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0070","first-page":"1","article-title":"Clinical performance of LOCITM-based tumor marker assays for tumor markers CA 15-3, CA 125, CEA, CA 19-9 and AFP in gynecological cancers","author":"Dolscheid-Pommerich","year":"2017","journal-title":"Tumor Biol."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0075","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ygyno.2018.03.050","article-title":"A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma","volume":"149","author":"Han","year":"2018","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0080","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer Immunoediting: integrating Immunity\u2019s roles in Cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2020.09.025_bb0085","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1136\/ijgc-2019-000521","article-title":"Myeloid-derived suppressor cells at diagnosis may discriminate between benign and malignant ovarian tumors","volume":"29","author":"Coosemans","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.ygyno.2020.09.025_bb0090","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1046\/j.1469-0705.2000.00287.x","article-title":"Terms, definitions and measurements to describe the sonographic features of adnexal tumors: a consensus opinion from the international ovarian tumor analysis (IOTA) group","volume":"16","author":"Timmerman","year":"2000","journal-title":"Ultrasound Obstet. Gynecol."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0095","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1093\/jnci\/dji237","article-title":"Reporting recommendations for tumor marker prognostic studies (REMARK)","volume":"97","author":"McShane","year":"2005","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0100","doi-asserted-by":"crossref","unstructured":"J. Prat, F. Committee. International Journal of Gynecology and Obstetrics Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int. J. Gynecol. Obstet. 2014; 124:1\u20135.","DOI":"10.1016\/j.ijgo.2013.10.001"},{"key":"10.1016\/j.ygyno.2020.09.025_bb0105","first-page":"1","article-title":"Mice: Multivariate imputation by chained equations in R","volume":"45","author":"Van Buuren","year":"2011","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0110","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/0962280207087173","article-title":"Comparison of non-parametric confidence intervals for the area under the ROC curve of a continuous-scale diagnostic test","volume":"17","author":"Qin","year":"2008","journal-title":"Stat. Methods Med. Res."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0115","series-title":"Introduction in: Regression Modeling Strategies","author":"Harrell","year":"2015"},{"key":"10.1016\/j.ygyno.2020.09.025_bb0120","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1093\/biomet\/80.1.27","article-title":"Bias reduction of maximum likelihood estimates","author":"Firth","year":"1993","journal-title":"Biometrika"},{"key":"10.1016\/j.ygyno.2020.09.025_bb0125","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.2147\/CMAR.S155693","article-title":"Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors","volume":"10","author":"Chen","year":"2018","journal-title":"Cancer Manag. Res."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0130","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta22440","article-title":"Risk scores to guide referral decisions for people with suspected ovarian cancer in secondary care: a systematic review and cost-effectiveness analysis","volume":"22","author":"Westwood","year":"2018","journal-title":"Health Technol. Assess."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0135","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1126\/science.320.5872.38","article-title":"All in the stroma: Cancer\u2019s Cosa Nostra","volume":"320","author":"Marx","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2020.09.025_bb0140","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1158\/1055-9965.EPI-14-1279-T","article-title":"Inflammatory markers and risk of epithelial ovarian cancer by tumor subtypes: The EPIC cohort","volume":"24","author":"Ose","year":"2015","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0145","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1158\/1055-9965.EPI-16-0120","article-title":"Inflammatory markers of CRP, IL6, TNF\u03b1, and soluble TNFR2 and the risk of ovarian cancer: a meta-analysis of prospective studies","volume":"25","author":"Zeng","year":"2016","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0150","article-title":"C-reactive protein and risk of ovarian cancer: a systematic review and meta-analysis","volume":"96","author":"Li","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ygyno.2020.09.025_bb0155","first-page":"1151","article-title":"C-reactive protein and ovarian cancer: a prospective study nested in three cohorts (Sweden, USA, Italy)","volume":"20","author":"Lundin","year":"2009","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ygyno.2020.09.025_bb0160","first-page":"15","article-title":"Associations of circulating C-reactive protein and interleukin-6 with cancer risk: findings from two prospective cohorts and a meta-analysis","volume":"20","author":"Heikkil\u00e4","year":"2009","journal-title":"Cancer Causes Control"},{"key":"10.1016\/j.ygyno.2020.09.025_bb0165","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1677\/ERC-10-0053","article-title":"Obesity, inflammatory markers, and endometrial cancer risk: A prospective case - control study","volume":"17","author":"Dossus","year":"2010","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ygyno.2020.09.025_bb0170","doi-asserted-by":"crossref","first-page":"2872","DOI":"10.1158\/1055-9965.EPI-08-0464","article-title":"Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer","volume":"17","author":"Bertenshaw","year":"2008","journal-title":"Cancer Epidemiol. Biomark. Prev."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0175","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1007\/s12032-009-9366-x","article-title":"Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer","volume":"27","author":"Zohny","year":"2010","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0180","first-page":"33","article-title":"Serum expression level of cytokine and chemokine correlates with progression of human ovarian cancer","volume":"38","author":"Luo","year":"2017","journal-title":"Eur. J. Gynaecol. Oncol."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0185","doi-asserted-by":"crossref","first-page":"2223","DOI":"10.1158\/1078-0432.CCR-16-1078","article-title":"Chromosomal instability in cell-free DNA as a highly specific biomarker for detection of ovarian Cancer in women with adnexal masses","volume":"23","author":"Vanderstichele","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ygyno.2020.09.025_bb0190","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1126\/science.aar3247","article-title":"Detection and localization of surgically resectable cancers with a multi-analyte blood test","volume":"359","author":"Cohen","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ygyno.2020.09.025_bb0195","doi-asserted-by":"crossref","first-page":"5920","DOI":"10.1136\/bmj.g5920","article-title":"Evaluating the risk of ovarian cancer before surgery using the ADNEX model to differentiate between benign, borderline, early and advanced stage invasive, and secondary metastatic tumours: prospective multicentre diagnostic study","volume":"349","author":"Van Calster","year":"2014","journal-title":"BMJ"},{"key":"10.1016\/j.ygyno.2020.09.025_bb0200","article-title":"Validation of models to diagnose ovarian cancer in patients managed surgically or conservatively: multicentre cohort study","volume":"370","author":"Van Calster","year":"2020","journal-title":"BMJ"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820339184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825820339184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:54:36Z","timestamp":1758772476000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825820339184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["S0090825820339184"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.09.025","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Assessment of protein biomarkers for preoperative differential diagnosis between benign and malignant ovarian tumors","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2020.09.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}